GenAI trends shaping evidence, engagement & impact in 2026

​Generative AI (GenAI) is moving fast in Medical Affairs – but where is it truly delivering value, and where are leaders focusing investment next?​

Watch this expert-led PharmaBrands webinar – sponsored by Inizio – to explore what Medical Affairs teams learned about GenAI in 2025, and what they are actively funding and scaling in 2026. You’ll hear real-world examples from organizations already applying GenAI to accelerate evidence generation, scientific content development, and stakeholder engagement – with the right balance of automation and human oversight.​

Joined by Phil Wakefield, Chief Strategy and Commercial Officer at Inizio Medical, experts from Boehringer Ingelheim and Vertex Pharmaceuticals discuss:​

• The AI standard for 2026: A clear view of 2025 GenAI trends in Medical Affairs – what delivered measurable impact, what didn’t, and where leaders are allocating budget and resources in 2026.​
• The true value of AI agents: A practical, technical look at how internal AI agents can synthesize insights across labels, trial protocols, FAQs, publications, and internal data sources to support faster, more accurate decision-making.​
• What’s ready for GenAI today and what isn’t: An honest assessment of which Medical Affairs processes can be effectively augmented now, and which still require strong human-led control to ensure scientific rigor and compliance.​

Leading the future of Intelligent Commercialization™​

As the webinar sponsor, Inizio works with health and life sciences organizations to enable Intelligent Commercialization™ – bringing together data, technology, AI, and human expertise to support better decision-making across the lifecycle. Discover more about Intelligent Commercialization™.

Watch the on-demand webinar here.